Bora establishes a leadership position in Taiwan's CDMO sector as it continues 
to expand into the global CDMO market


Taiwan-based premier international contract development and manufacturing 
organization (CDMO) Bora Pharmaceuticals recently announced the establishment 
of Bora Biologics Co., Ltd., a CDMO platform for biologics. Besides Bora, 
investors into the new entity include Taishin Healthcare Limited Partnership 
and Tanvex BioPharma founder Dr. Allen Chao. Bora also announced that they will 
initially invest $50 million USD and up to $100 million USD in the acquisition 
of Eden Biologics' CDMO assets in Taiwan as part of its 5-year growth plan. 
With Bora's strengths as a CDMO for small molecules and biological 
macromolecules, the company has established a leadership position in Taiwan 
with its comprehensive CDMO customer services and competitive market share.

In line with its strategy of building comprehensive CDMO capabilities, Bora 
expands into biologic macromolecules and cell and gene therapy markets

Bora indicated that the strategic acquisition of Eden Biologics CDMO assets, 
located in Hsinchu Biomedical Science Park, Taiwan,  will help Bora Group 
rapidly build a presence in the biological macromolecules and cell and gene 
therapy markets, and position the organization to expand its service offering 
to their clients supporting new and innovative drug development. 

Bora chairman Bobby Sheng explained that the acquisition of Eden Biologic's 
CDMO assets is an important milestone as Bora continues to expand its presence 
in the CDMO market. Bora has always been committed to the creation of a global 
CDMO with comprehensive capabilities. The strategic cooperation with Taishin 
Healthcare Limited Partnership and Dr. Allen Chao is in line with the firm's 
long-term investment strategy for growth. 

Expanding production capacity with international standards-based manufacturing 
processes and technologies

With the acquisition of the facility, Bora will have biopharmaceutical 
technologies related to the development of cell lines for the production of 
protein drugs, the development and analysis of upstream and downstream 
processes, along with the establishment of quality control and inspection 
specifications, as well as cell bank generation.

"The addition of the CDMO facilities state of the art equipment and the 
expertise of the highly qualified team gives Bora Biologics the ability to 
develop and continue with our clients as they progress to commercialization." 
Bora Vice President Simon Chen said.

Mr. Chen further explained that the facility has four 500L bioreactors, all of 
which have been certified by the EU Qualified Person (QP) and the Taiwan Food 
and Drug Administration, Ministry of Health and Welfare. The facility has 
proven its comprehensive CDMO capabilities by having completed several 
collaborative projects with many international partners.

Bora Pharmaceuticals is a premier international CDMO specializing in a wide 
range of complex dosage forms including oral solid, liquid, and semi-solid 
capabilities for both Rx and OTC products, as well as, macromolecule 
biologics.  Bora owns and operates multiple cGMP manufacturing facilities in 
Asia and North America offering services for clinical and commercial 
manufacturing, packaging, and analytical testing.  For more information 
contact: info@bora-corp.com

SOURCE:  Bora corp

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=420864

   Caption: Eden Biologics CDMO assets, located in Hsinchu Biomedical Science 
Park, Taiwan